Zealand Pharma (ZEAL.CO)

Executive Summary

Zealand Pharma is a Copenhagen-based biotechnology company specializing in peptide-based therapeutics for metabolic and gastrointestinal diseases, with a strong focus on obesity, type 2 diabetes, and rare conditions. The company leverages proprietary peptide engineering to develop innovative therapies addressing significant unmet medical needs. Its pipeline includes late-stage programs such as glepaglutide for Short Bowel Syndrome (SBS) and dasiglucagon for Congenital Hyperinsulinism (CHI), alongside early-stage candidates. With two approved products and strategic partnerships, Zealand Pharma is positioned to deliver value in high-demand therapeutic areas. Upcoming catalysts include top-line Phase 3 data for glepaglutide in SBS, expected in Q2 2026, which could support a regulatory filing. Additionally, a potential NDA submission for dasiglucagon in CHI is anticipated in the second half of 2026, following positive Phase 2/3 results. The combination of a robust pipeline, proven technology, and commercial partnerships supports a positive outlook, though execution risks remain.

Upcoming Catalysts (preview)

• Q2 2026Glepaglutide Phase 3 Top-Line Data in Short Bowel Syndrome80% success
• H2 2026Dasiglucagon NDA Submission for Congenital Hyperinsulinism60% success